**A black background with a black square

Description automatically generated with medium confidence**

**A new standard in breast imaging: (Facility name) Launches SecondReadAI™, powered by Lunit**

**[City, State]** – [Facility Name] is setting a new benchmark in breast cancer detection with the introduction of SecondReadAI™, powered by Lunit. This advanced AI technology serves as a second opinion for radiologists, designed to provide decision support and give patients heightened confidence in their mammogram results. By enhancing early-stage cancer detection up to 15% beyond mammography alone1, SecondReadAI is an invaluable tool to help identify fine details that may otherwise be overlooked.

SecondReadAI is particularly beneficial in assessing dense breast tissue, a common factor that makes mammogram readings challenging. Studies show that with SecondReadAI, radiologists are able to increase overall cancer detection rates by 10%2 and remarkably reduce unnecessary callbacks3, false positives3, and benign biopsies4.

SecondReadAI uses its precise, subclinical analysis to highlight areas that may be difficult for the human eye to detect, offering radiologists additional confidence in their interpretations and enhancing accuracy in mammogram readings. This close collaboration between technology and radiologists supports more reliable diagnoses and ultimately, better patient care.

“SecondReadAI represents a breakthrough in mammogram analysis, empowering our radiologists and offering patients added peace of mind with every exam,” said [Name, Title]. “Our commitment is to provide the most accurate screenings possible. This technology strengthens our mission and helps improve patient outcomes.”

“Breast cancer remains one of the most prevalent cancers. We know that many patients approach their mammogram appointments with a mix of hope and concern," said Teri Thomas, Volpara CEO and Lunit Chief Business Officer. "SecondReadAI offers an added level of reassurance, providing patients and radiologists alike with the confidence that images are reviewed with advanced precision, ultimately elevating the reliability of mammogram results.”

The launch of SecondReadAI demonstrates [Facility Name]’s dedication to advancing the standard of care in breast imaging. Now available as an optional, out-of-pocket service, SecondReadAI can be easily added to a mammogram appointment without additional imaging or appointment time. Patients can use Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) as a payment option. Currently, SecondReadAI is available at [list locations], with plans to expand to additional imaging centers soon. For more information, visit XXX.com.

1. Hyo Eun Kim, et al., Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multi reader study, The Lancet Digital Health, 2020
2. Eun Kyung Park, et al., Impact of AI for Digital Breast Tomosynthesis on Breast Cancer Detection and Interpretation Time, Radiology: Artificial Intelligence 2024; 6(3):e230318
3. Lee, Si Eun, et al., Comparison of conventional CAD and AI-CAD applied to digital mammography in respect of false-positive marks, Journal of the Korean Society for Breast Screening, 2020
4. Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DS, Kerlikowske K, et al. National performance benchmarks for modern screening digital mammography: update from the Breast Cancer Surveillance Consortium. Radiology 2017;283:49-58

**About (Company Name)**

Company boilerplate language

**About Lunit**

Founded in 2013, Lunit is a medical AI company on a mission to conquer cancer. We harness AI-powered medical image analytics and AI biomarkers to ensure accurate diagnosis and optimal treatment for each cancer patient. Our FDA-cleared Lunit INSIGHT suite for cancer screening serves over 3,000 hospitals and medical institutions across 40+ countries.

Our clinical findings are featured in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA.

In 2024, Lunit acquired Volpara Health Technologies, setting the stage for unparalleled synergy and accuracy, particularly in breast health and screening technologies.

Headquartered in Seoul, South Korea, with a global network of offices, Lunit leads in medical AI innovation. Discover more at lunit.io

#   #   #

Media Contact:

Individual Name

Title

Company name

Telephone number

[email](mailto:Erica.Carnevale@VolparaHealth.com) address

Media Contact:


Erica Carnevale

Director, Marketing

Volpara Health / Lunit

(315) 842-0270

[Erica.Carnevale@VolparaHealth.com](mailto:Erica.Carnevale@VolparaHealth.com)

**

This AI software cannot guarantee breast cancer detection with 100% accuracy.

SecondReadAI is a trademark of Lunit® Inc.

MKT8842-2